10-Q · May 5, 2026
Bowhead Specialty Holdings achieved impressive results for Q1 2026, reporting revenues of $155.7 million, a 26.9% increase year-over-year, alongside an EPS of $0.48, surpassing estimates by $0.06. Management highlighted…
Earnings analysis · 10-Q
BOW earnings analysis
Filed August 3, 2026 · Our reading of the company's report
The latest report
Bowhead delivered a solid Q2 operating result: revenue increased 23.0% to $163.857 million, diluted EPS increased 33.3% to $0.48, and the combined ratio improved to 95.9%. Premium growth was broad based, led by…
Read full summary
Bowhead delivered a solid Q2 operating result: revenue increased 23.0% to $163.857 million, diluted EPS increased 33.3% to $0.48, and the combined ratio improved to 95.9%. Premium growth was broad based, led by Casualty's $49.044 million increase and Baleen Specialty's 311.1% growth, while operating cash flow reached $159.339 million for the first half. Offsetting factors include a higher 67.3% loss ratio, sharply higher reinsurance cessions, and material execution uncertainty from the proposed American Family merger announced August 3, 2026.
Gross and operating margin
How much of each revenue dollar the business keeps.
One point per quarterly or annual filing. Both margins are shares of that report's revenue.
Where revenue came from
The business segments reported by the company.
Shares of the segments disclosed in this filing, largest first.
How we read each report
Our analysis across the last few reports.
Our model's reading of each filing, not the share price or the market's reaction. Annual and quarterly reports each occupy one position.
Reported figures
- Earnings per share
- $0.48
What stood out
-
Revenue and EPS grew strongly year over year
Q2 total revenue rose $30.594 million, or 23.0%, year over year to $163.857 million; it also increased $7.857 million, or 5.0%, from Q1 2026 revenue of $156.000 million. Diluted EPS was $0.48, up $0.12, or 33.3%, from $0.36 a year earlier and flat sequentially.
-
Combined ratio improved below 100%
Underwriting profitability improved as the combined ratio declined 0.9 points to 95.9% from 96.8%. The expense ratio fell 2.0 points to 28.6%, more than offsetting a 1.1-point increase in the loss ratio to 67.3%.
-
Premium growth led by Casualty and Baleen
Gross written premiums increased $65.533 million, or 28.2%, to $297.894 million. Casualty contributed $49.044 million of the increase, while Baleen Specialty increased $10.528 million, or 311.1%, to $13.912 million.
-
Net income and investment income accelerated
Net income rose $3.796 million, or 30.8%, to $16.138 million, aided by a $5.143 million, or 37.6%, increase in net investment income to $18.820 million. Underwriting income increased $1.454 million, or 43.4%, to $4.804 million.
-
Operating cash generation remained robust
Six-month operating cash flow was $159.339 million, up $2.637 million from $156.702 million a year earlier. Property-and-equipment purchases were $2.6 million, implying approximately $156.7 million of free cash flow and capex intensity of roughly 0.8% of $319.551 million six-month revenue.
-
Liquidity and capital base remain solid
Liquidity includes $65.3 million of holding-company cash and investments, no borrowings under the $35 million revolving facility, and $150 million remaining under the shelf registration statement. Total mezzanine and stockholders' equity increased $24.6 million to $473.9 million from $449.3 million at December 31, 2025.
What to watch
-
Loss and acquisition-cost pressure increased
The loss ratio increased 1.1 points year over year to 67.3%, driven by lower ceded-loss activity under excess-of-loss treaties and portfolio mix. Net acquisition costs increased $4.782 million, or 43.3%, and the acquisition-cost ratio rose 1.7 points to 11.0%.
-
New merger approval and execution risk
The new August 3, 2026 merger risk factors state that closing requires two separate majority stockholder approvals, plus HSR and Wisconsin and Texas insurance-regulator approvals. Pending closing, operating restrictions and uncertainty could disrupt insured, broker, and employee relationships.
-
Greater reinsurance reliance and cap exposure
The company increased its quota-share cession to 33.5% from 26.0%, effective May 1, 2026, contributing to ceded written premiums rising 39.9% to $116.869 million. Reinsurance treaty caps range from 250% to 350% of subject ceded premium, beyond which Bowhead retains losses.
-
Reserve estimates remain highly sensitive
Net unpaid loss and loss-adjustment-expense reserves increased $116.305 million to $864.544 million since December 31, 2025, with 90.3% classified as IBNR. A 7.5% adverse reserve change in Casualty alone would reduce pretax income by $43.595 million.
-
Debt cost and investment-rate sensitivity
Interest expense and financing fees rose $3.005 million to $3.266 million year over year following issuance of $150 million of 7.75% senior notes due December 1, 2030. A 200-basis-point rate increase would reduce the fair value of fixed maturities and cash by $104.517 million, or 6.4%.
Management's outlook
No quantitative financial guidance was provided in the 10-Q. Management stated it believes liquidity is sufficient for operating needs and obligations for at least the next 12 months; the pending American Family merger is subject to stockholder and regulatory approvals.
Earlier filings 4
10-K · February 24, 2026
Bowhead reported strong premium growth and widening product mix in 2025, with gross written premiums rising to $862,806,000 (from $695,717,000 in 2024) while maintaining an underwriting-first strategy supported by its…
10-Q · November 4, 2025
Bowhead reported 3Q25 revenue of $143,932,000 and diluted EPS of $0.45, driven by higher gross written premiums and stronger investment income. Net earned premiums rose to $128,407,000 and operating cash generation…
10-Q · May 6, 2025
Bowhead reported Q1 2025 revenues of $122.716M (vs $90.672M in Q1 2024) and diluted EPS of $0.34. Revenue and net income grew meaningfully year-over-year while management increased investments and underwriting scale;…
This is our reading of a public filing, not the filing itself. Analysis can contain errors; check the source document for full context.